1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Comparison of patients with and without arterial reocclusion
Total (n = 91)Reocclusion (n = 16)No Reocclusion (n = 75)P Value
Mean age (years)67 ± 1570 ± 1466 ± 16.58
Male patients (No., %)48 (53)8 (50)40 (53).81
Occlusion site:.92
    MCA48 (53%)9 (56%)39 (52%)
    ICA29 (32%)5 (31%)24 (32%)
    ACA2 (2%)0 (0%)2 (3%)
    BA12 (13%)2 (13%)10 (13%)
Study protocol*.18
    Group 147 (52%)9 (56%)38 (51%)
    Group 212 (13%)4 (25%)8 (11%)
    Group 319 (21%)3 (19%)16 (21%)
    Group 413 (14%)0 (0%)13 (17%)
Mean time to treatment (h)4.36 ± 2.184.05 ± 1.274.42 ± 2.33.06
Initial Qureshi grade 0–3B53 (58%)9 (56%)44 (59%).86
Initial Qureshi grade 4A-538 (42%)7 (44%)31 (41%)
Final recanalization†<.01
    None19 (21%)2 (13%)17 (23%)
    Partial41 (45%)13 (82%)28 (37%)
    Complete29 (32%)1 (6%)28 (37%)
Symptomatic ICH (No.)1037.46
Median initial NIHSS score19 (±8)19 (±7)19 (±8).90
Median 24-hour NIHSS score18 ± 1322 (±11)17 (±13).18
Median 7-day NIHSS score18 ± 1625 (±16)17 (±16).06
Favorable mRS‡ at 1–3 months (No., %)29 (32)1 (6)28 (37).02
Favorable 1–3 mRS at 1–3 months among treatment responders§ (n = 70)24/70 (34%)1/16 (6%)23/56 (41%).01
  • Note:—MCA indicates middle cerebral artery; ICA, internal carotid artery; ACA, anterior cerebral artery; BA, basilar artery; h, hour; ICH, intracerebral hemorrhage; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale.
  • * Group 1, IA reteplase and MTD; group 2, EKOS MicroLysUS North American trial; group 3, MTD following IV thrombolysis; group 4, IA reteplase and IV abciximab (FDA IND 9180).
  • † Defined as ≤2.
  • ‡ Data were missing on 2 patients.
  • § Patients who never demonstrated recanalization were excluded from the analysis.